ClinicalTrials.gg
RecruitingNCT07620392dRAvite-LTEUpdated Oct 16, 2026

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

A Phase 2 interventional study of Afimkibart in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Recruiting at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 16, 2026First site in Brazil4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.

Planned enrollment
74th of 141
120 · median 132
Started
2026
the only one that year
Phase 2
20 of 219
2 open now
Registered
219th of 219
by date

Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 74th largest by planned enrollment of the 141 interventional ones that give a count, is the only one that started in 2026, is one of 20 in phase 2, and was the 219th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The study will evaluate the long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with moderate to severe Rheumatoid Arthritis (RA) who have an inadequate response or intolerance to tumor necrosis factor (TNF) and/or Janus kinase (JAK) inhibitors, and who were previously treated with Afimkibart.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed the treatment period of the parent study
  • Agreement to adhere to the requirements
  • Continued to be evaluated at the follow-up visit of the parent study and achieved improvement in the SJC66/TJC68 relative to baseline

Exclusion criteria

Exclusion Criteria:

  • Withdrawal of consent and/or premature discontinuation from parent study
  • Any permanent discontinuation of study drug in parent study
  • Use of a prohibited therapy during the parent study
  • Evidence of any new or uncontrolled concomitant disease that, in the investigator's judgment, would preclude participant participation in the trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Afimkibart Group I

    Participants will recieve Afimkibart as subcutaneous (SC) injection.

    Drug: Afimkibart

  • Experimental
    Afimkibart Group II

    Participants will receive Afimkibart as SC injection.

    Drug: Afimkibart

Interventions

  • Participants will receive Afimkibart as per the schedule mentioned in the protocol.

    Also known as: PF-06480605, RVT-3101, RO7790121

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    Time frame: From Baseline up to 6 years

Secondary outcomes

  1. Percentage of Participants Achieving an American College of Rheumatology 20 Percent (%), 50% or 70% Improvement (ACR20/ACR50/ACR70)

    Time frame: Up to 6 years

  2. Change from baseline in Individual Components of ACR

    Time frame: Baseline, Up to 6 years

  3. Change From Baseline in Disease Activity Score-28 for Rheumatoid Arthritis With C-Reactive Protein (DAS28-CRP)

    Time frame: Baseline, Up to 6 years

  4. Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28-CRP Score

    Time frame: Up to 6 years

  5. Percentage of Participants LDA Achieving Based on Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation (DAS28-ESR) Score

    Time frame: Up to 6 years

  6. Percentage of Participants Achieving LDA Based Clinical Disease Activity Index (CDAI) Score

    Time frame: Up to 6 years

  7. Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28-CRP Score

    Time frame: Up to 6 years

  8. Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28-ESR Score

    Time frame: Up to 6 years

  9. Percentage of Participants Achieving Clinical Remission (CR) Based on CDAI Score

    Time frame: Up to 6 years

  10. Percentage of Participants Achieving Clinical Remission (CR) Based on SDAI Score

    Time frame: Up to 6 years

  11. Serum Concentration of Afimkibart

    Time frame: Up to 6 years

  12. Percentage of Participants with Anti-Drug Antibodies (ADAs) to Afimkibart at Baseline and with ADAs to Afimkibart During the Study

    Time frame: Baseline, Up to 6 years

  13. Percentage of Participants with Neutralizing Antibody (NAb) to Afimkibart

    Time frame: Up to 6 years

07

Study locations

12 of 12 sites recruiting
  • Arthritis and Rheumatic Disease Specialty Inc
    Tamarac, Florida 33321, United States
    Recruiting
  • Accurate Clinical Research Inc.
    Lake Charles, Louisiana 70605, United States
    Recruiting
  • Accurate Clinical Management LLC
    Houston, Texas 77089, United States
    Recruiting
  • DM Clinical Research at Tomball
    Tomball, Texas 77375, United States
    Recruiting
  • Rheumatic Disease Center
    Glendale, Wisconsin 53217, United States
    Recruiting
  • Centro Mineiro de Pesquisa - CMIP
    Juiz de Fora, Minas Gerais 36010-570, Brazil
    Recruiting
  • Centrum Medyczne Reuma Park
    Warsaw, Masovian Voivodeship 02-665, Poland
    Recruiting
  • Nzoz Bif-Med
    Bytom, 41-902, Poland
    Recruiting
  • Centrum Kliniczno-Badawcze J. Brzezicki, B. Górnikiewicz-Brzezicka Lekarze Spó?ka Partne
    Elblag, 82-300, Poland
    Recruiting
  • Zespol Poradni Specjalistycznych REUMED filia nr 1 Wallenroda
    Lublin, 20-607, Poland
    Recruiting
  • Twoja Przychodnia NCM
    Nowa Sól, 67-100, Poland
    Recruiting
  • Reumatop Grzegorz Rozumek Karin Pistorius Spolka Jawna
    Wroclaw, 52-210, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jul 2033, 85 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 85 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 2, 2026
StartActual
Jun 3, 2026
Primary completionEst.
Jul 8, 2033
CompletionEst.
Jul 8, 2033
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 2 sites removed — first site in Brazil
Show 4 added (3 United States, 1 Brazil)
  • Arthritis and Rheumatic Disease Specialty Inc · Tamarac, United States
  • DM Clinical Research at Tomball · Tomball, United States
  • Rheumatic Disease Center · Glendale, United States
  • Centro Mineiro de Pesquisa - CMIP · Juiz de Fora, Brazil
Show 2 removed
  • West Broward Rheumatology Associates, Inc. · Tamarac, United States
  • DM Clinical Research · Tomball, United States
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    4 sites added, 2 sites removed — first site in Brazil
    Show 4 added (3 United States, 1 Brazil)
    • Arthritis and Rheumatic Disease Specialty Inc · Tamarac, United States
    • DM Clinical Research at Tomball · Tomball, United States
    • Rheumatic Disease Center · Glendale, United States
    • Centro Mineiro de Pesquisa - CMIP · Juiz de Fora, Brazil
    Show 2 removed
    • West Broward Rheumatology Associates, Inc. · Tamarac, United States
    • DM Clinical Research · Tomball, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07620392
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jun 3, 2026
Primary completion
Jul 8, 2033 (estimated)
Completion
Jul 8, 2033 (estimated)
Last update
Oct 16, 2026

Study contacts

Reference Study ID Number: WA46440 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimkibart

Start the discussion